Published in World J Urol on February 12, 2013
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma | NCT01265901
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol (2014) 2.78
SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines. Expert Rev Vaccines (2014) 0.85
Checkpoint modulation--A new way to direct the immune system against renal cell carcinoma. Hum Vaccin Immunother (2015) 0.83
Tumour and patient factors in renal cell carcinoma-towards personalized therapy. Nat Rev Urol (2015) 0.78
Systemic therapy in metastatic renal cell carcinoma. World J Urol (2016) 0.77
Specific immunotherapy in renal cancer: a systematic review. Ther Adv Urol (2016) 0.75
Polypoid Gallbladder Lesion in the Context of Renal Cell Carcinoma: Is Laparoscopic Cholecystectomy a Reasonable Option? J Investig Med High Impact Case Rep (2013) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39
Cancer-related inflammation. Nature (2008) 34.21
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 14.57
EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol (2010) 8.21
The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer (2008) 7.40
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol (2010) 6.30
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44
Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res (2009) 5.10
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol (2010) 5.08
Peptides naturally presented by MHC class I molecules. Annu Rev Immunol (1993) 4.66
Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol (2010) 4.43
IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood (2005) 4.06
Immunopharmacology of rapamycin. Annu Rev Immunol (1996) 3.86
Tregs and rethinking cancer immunotherapy. J Clin Invest (2007) 3.77
Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res (2005) 3.74
Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol (2003) 3.38
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother (2007) 3.32
Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res (2008) 2.84
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 2.53
The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunol Immunother (2007) 2.49
Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res (2008) 2.26
Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood (2008) 2.09
Harmonization of immune biomarker assays for clinical studies. Sci Transl Med (2011) 1.84
Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer. Clin Cancer Res (2007) 1.84
Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J Immunol (1999) 1.71
Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci U S A (2010) 1.67
Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res (2006) 1.67
Spontaneous regression of metastatic renal cancer. Case report and literature review. Am J Clin Oncol (1997) 1.37
Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res (2010) 1.30
Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res (2002) 1.28
Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer (2003) 1.24
Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate (2009) 1.20
Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. Cancer Res (2009) 1.19
A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma. Clin Cancer Res (2006) 1.15
A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin Cancer Res (2009) 1.12
Emerging immunotherapies for renal cell carcinoma. Ann Oncol (2012) 1.11
Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines. J Immunol (1993) 1.08
Harmonization of the intracellular cytokine staining assay. Cancer Immunol Immunother (2012) 1.05
Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas. Clin Cancer Res (2006) 1.02
Immunotherapeutic strategies in kidney cancer--when TKIs are not enough. Nat Rev Clin Oncol (2009) 1.01
A soluble lymphocyte activation gene-3 molecule used as a vaccine adjuvant elicits greater humoral and cellular immune responses to both particulate and soluble antigens. J Immunol (2000) 0.95
Redirecting human T lymphocytes toward renal cell carcinoma specificity by retroviral transfer of T cell receptor genes. Hum Gene Ther (2005) 0.91
Second-line systemic therapy for the treatment of metastatic renal cell cancer. Expert Rev Anticancer Ther (2012) 0.87
Immunological effects of multikinase inhibitors for kidney cancer: a clue for integration with cellular therapies? J Cancer (2011) 0.84
Higher HLA class I expression in renal cell carcinoma than in autologous normal tissue. Tissue Antigens (2009) 0.83
Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy. Cancer J (2011) 0.83
Vaccination therapy in renal cell carcinoma: current position and future options in metastatic and localized disease. Expert Rev Vaccines (2011) 0.77
Retracted Generation of pluripotent stem cells from adult human testis. Nature (2008) 5.49
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44
Adjuvant radiotherapy for patients with locally advanced prostate cancer--a new standard? Eur Urol (2008) 3.27
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
In vitro investigations of tissue-engineered multilayered urothelium established from bladder washings. Eur Urol (2008) 2.84
Urinary diversion. Urology (2007) 2.65
Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol (2008) 2.48
Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol (2009) 2.45
The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway. J Biol Chem (2002) 2.39
The periprostatic autonomic nerves--bundle or layer? Eur Urol (2008) 2.38
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol (2012) 2.19
Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood (2008) 2.09
Inflammatory prognostic markers in clear cell renal cell carcinoma - preoperative C-reactive protein does not improve predictive accuracy. BJU Int (2012) 1.99
Moderate degradation does not preclude microarray analysis of small amounts of RNA. Biotechniques (2003) 1.95
Epstein-Barr nuclear antigen 1-specific CD4(+) Th1 cells kill Burkitt's lymphoma cells. J Immunol (2002) 1.92
Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. Brain (2012) 1.92
Cytomegalovirus infection: a driving force in human T cell immunosenescence. Ann N Y Acad Sci (2007) 1.87
Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines. Proc Natl Acad Sci U S A (2002) 1.85
Early sacral neuromodulation prevents urinary incontinence after complete spinal cord injury. Ann Neurol (2010) 1.84
Harmonization of immune biomarker assays for clinical studies. Sci Transl Med (2011) 1.84
Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur Urol (2012) 1.81
Minimally invasive percutaneous nephrolithotomy: an alternative to retrograde intrarenal surgery and shockwave lithotripsy. World J Urol (2012) 1.72
HYAL-1 hyaluronidase: a potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancer. Eur Urol (2009) 1.72
Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection. J Urol (2008) 1.68
Totally intracorporeal replacement of the ureter using whole-mount ileum. J Endourol (2014) 1.67
Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol (2012) 1.63
More than just tumor destruction: immunomodulation by thermal ablation of cancer. Clin Dev Immunol (2011) 1.56
Y pouch neobladder-a simplified method of intracorporeal neobladder after robotic cystectomy. J Endourol (2014) 1.51
The commonly performed nerve sparing total prostatectomy does not acknowledge the actual nerve courses. J Urol (2009) 1.51
MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies. Eur Urol (2006) 1.50
Urethral ultrasound as a screening tool for stricture recurrence after oral mucosa graft urethroplasty. Urology (2011) 1.50
Point-of-Care Tests for Bladder Cancer: The Influencing Role of Hematuria. Adv Urol (2011) 1.49
Influence of urinary tract instrumentation and inflammation on the performance of urine markers for the detection of bladder cancer. Urology (2012) 1.47
Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein. Eur J Immunol (2003) 1.46
Quantification of tumor cell burden by analysis of single cell lymph node disaggregates in metastatic prostate cancer. Prostate (2010) 1.45
Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. 1991. J Immunol (2006) 1.45
Enzalutamide in European and North American men participating in the AFFIRM trial. BJU Int (2014) 1.43
Radical cystectomy and orthotopic bladder replacement in females. Eur Urol (2006) 1.42
Dorsal onlay skin graft urethroplasty in patients older than 65 years. Urology (2010) 1.41
Immunoreactivity of p63 in monolayered and in vitro stratified human urothelial cell cultures compared with native urothelial tissue. Eur Urol (2007) 1.41
Prolonged percutaneous SNM testing does not cause infection-related explanation. BJU Int (2012) 1.41
Tissue engineering for the lower urinary tract: a review of a state of the art approach. Eur Urol (2007) 1.41
Steerable antegrade stenting: a new trick of the trade. Int Braz J Urol (2007) 1.39
Urinary calculi composed of uric acid, cystine, and mineral salts: differentiation with dual-energy CT at a radiation dose comparable to that of intravenous pyelography. Radiology (2010) 1.39
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J Clin Oncol (2013) 1.38
Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur Urol (2011) 1.36
Hierarchical modeling for rare event detection and cell subset alignment across flow cytometry samples. PLoS Comput Biol (2013) 1.35
Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther (2010) 1.32
Expansion and differentiation of neural progenitors derived from the human adult enteric nervous system. Gastroenterology (2009) 1.32
Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur Urol (2009) 1.32
Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes. BJU Int (2014) 1.31
Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res (2002) 1.28
Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface. Mol Cell Proteomics (2006) 1.26
Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol (2013) 1.25
Urothelial carcinoma of the bladder and the upper tract: disparate twins. J Urol (2012) 1.25
Towards patient-specific tumor antigen selection for vaccination. Immunol Rev (2002) 1.22
Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate (2009) 1.20
Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. Cancer Res (2009) 1.19
Mouse urinary peptides provide a molecular basis for genotype discrimination by nasal sensory neurons. Nat Commun (2013) 1.18
Cross-protective TH1 immunity against Aspergillus fumigatus and Candida albicans. Blood (2011) 1.18
Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Eur Urol (2008) 1.16
Fibronectin 1 mRNA expression correlates with advanced disease in renal cancer. BMC Cancer (2010) 1.14
Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. Eur Urol (2013) 1.12
Extracorporeal shock wave therapy in Peyronie's disease: results of a placebo-controlled, prospective, randomized, single-blind study. J Sex Med (2013) 1.11
Closing the tract of mini-percutaneous nephrolithotomy with gelatine matrix hemostatic sealant can replace nephrostomy tube placement. Urology (2006) 1.10
A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer. Cancer Biother Radiopharm (2009) 1.10
HLA ligand profiles of primary renal cell carcinoma maintained in metastases. Cancer Immunol Immunother (2009) 1.08
Nucleosome, the main autoantigen in systemic lupus erythematosus, induces direct dendritic cell activation via a MyD88-independent pathway: consequences on inflammation. J Immunol (2005) 1.08
Features of TAP-independent MHC class I ligands revealed by quantitative mass spectrometry. Eur J Immunol (2008) 1.08
Urethrovaginal fistula--a rare complication after the placement of a suburethral sling (IVS). Int Urogynecol J Pelvic Floor Dysfunct (2006) 1.07
Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase. Clin Cancer Res (2013) 1.05
Identification of HLA-DR-bound peptides presented by human bronchoalveolar lavage cells in sarcoidosis. J Clin Invest (2007) 1.05
Harmonization of the intracellular cytokine staining assay. Cancer Immunol Immunother (2012) 1.05
Accuracy of preoperative endorectal MRI in predicting extracapsular extension and influence on neurovascular bundle sparing in radical prostatectomy. World J Urol (2012) 1.04
Quantitative analysis of prion-protein degradation by constitutive and immuno-20S proteasomes indicates differences correlated with disease susceptibility. J Immunol (2004) 1.04
Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study. BJU Int (2012) 1.04
The heat shock protein Gp96 binds to human neutrophils and monocytes and stimulates effector functions. Blood (2002) 1.03
Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy. Cancer Immunol Immunother (2004) 1.03
Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma. Cancer Immunol Immunother (2012) 1.02
Insights into MHC class I antigen processing gained from large-scale analysis of class I ligands. Cell Mol Life Sci (2011) 1.02
In vitro myogenic differentiation of human bone marrow-derived mesenchymal stem cells as a potential treatment for urethral sphincter muscle repair. Ann N Y Acad Sci (2009) 1.02
Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas. Clin Cancer Res (2006) 1.02
Investigations of urothelial cells seeded on commercially available small intestine submucosa. Eur Urol (2006) 1.01
Gender-specific differences in bladder cancer: a retrospective analysis. Gend Med (2008) 1.01
Minimally invasive percutaneous nephrolitholapaxy (PCNL) as an effective and safe procedure for large renal stones. BJU Int (2012) 1.01